Aflivis 40 mg/ml, Injektionslösung

7680700610018 CH-70061 Injektionslösung

Associated product:

AFLIVIS 40 mg/ml sol inj 2 mg 1 pce

No image available

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
29/05/2026
Summary of Product Characteristics
Français
29/05/2026
Summary of Product Characteristics
Italien
29/05/2026

Detailed composition

Substance Quantity Type Category
afliberceptum
2.0 MG Substance Wirkstoff (Principe actif)
natrii acetas trihydricus
- Substance HNIDK
acidum aceticum glaciale
- Substance HNIDK
saccharum
- Substance HNIDK
natrii chloridum
- Substance HNIDK
polysorbatum 20
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
27.0 UG Substance HBESI

Authorization holder

OmniVision AG

8212 Neuhausen am Rheinfall

Authorization information

Swissmedic authorization number
70061
Drug name
Aflivis, Injektionslösung
Galenic form
LSINJ
ATC Code
S01LA05
Authorization status
Z
Dispensing category
B
First authorization
02/02/2026
Authorization expiration date
01/02/2031
IT Number
11.99.0.
Domain
Human medicine
Field of application
Exsudative (feuchte) altersbezogenen Makuladegeneration (AMD). Makulaödem infolge eines retinalen Zentralvenenverschlusses (CRVO) und retinalen Venenastverschlusses (BRVO), diabetisches Makulaödem (DME), Behandlung von subfovealen und juxtafovealen choroidalen Neovaskularisationen infolge einer pathologischen Myopie (mCNV).

Package details

Description (FR)
AFLIVIS 40 mg/ml sol inj 2 mg 1 pce
Description (DE)
AFLIVIS 40 mg/ml Inj Lös 2 mg 1 Stk
Market launch
01/10/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data